CMPX

TentativeAI Memo

Compass Therapeutics

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

COMPANION-002 data presentation at ESMO • 2026-10-31

Base target: $1 / p=45% prob

Biggest risk

Overall survival did not reach statistical significance, and the FDA recommended another trial before submission. A new trial could delay value realization and raise spending. Wedbush cut its target to $1 from $5 and downgraded to Neutral, while H.C. Wainwright cut its target to $12 from $24 but retained Buy, illustrating unusually wide disagreement. https://www.investing.com/news/analyst-ratings/wedbush-downgrades-compass-therapeutics-stock-rating-on-fda-trial-concerns-93CH-4911695 https://www.investing.com/news/analyst-ratings/hc-wainwright-cuts-compass-therapeutics-stock-price-target-on-fda-trial-recommendation-93CH-4912827

Invalidation

Break below $0 or thesis failure.

What would change my mind?

COMPANION-002 met its response-rate endpoint and showed a progression-free-survival benefit. If further FDA engagement permits a filing without a new survival trial, substantial upside remains possible; that outcome is not established. [#PR-2026-09-22] https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/exh_991.htm

Research note

Recommendation

—

Confidence

medium

As of

2026-10-02

Base target

p=45%

Bull target

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Early pipeline data test value beyond tovecimig
COMPANION-002 met its response-rate endpoint and showed a progression-free-survival benefit.
If further FDA engagement permits a filing without a new survival trial, substantial upside remains possible; that outcome is not established.

BearKey bullets

A longer development path could increase cash burn or financing needs; the June runway projection may change.
[#PR-EARNINGS-2026-08-06] https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm
COMPANION-002 overall survival was not statistically significant despite response-rate and progression-free-survival benefits.

WatchKey bullets

COMPANION-002 data presentation at ESMO

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Target spread vs base: +95% / -45%

Scenario probabilities

Bull Target: $2 (p=20%)Base Target: $1 (p=45%)Bear Target: $0 (p=35%)

Commentary

News tone is sharply negative after the September 22 FDA disclosure. Secondary coverage reported a steep immediate selloff, and the October 1 $0.9011 anchor is below the cited September 22 price of $1.24. Analyst target cuts are confirmed in secondary reporting, but targets diverge widely. Social, options, short-interest and employee metrics were unavailable; their zero entries are placeholders, not measured neutral readings. https://www.investing.com/news/analyst-ratings/hc-wainwright-cuts-compass-therapeutics-stock-price-target-on-fda-trial-recommendation-93CH-4912827

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Early pipeline data test value beyond tovecimig

Scenarios

Bull Target (Scenario probability)

$2 / p=20% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=35% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.80

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-31
COMPANION-002 data presentation at ESMO
Compass said the full tovecimig dataset was selected for an October oral presentation. Additional analysis may strengthen or weaken the clinical case, but a presentation alone cannot settle the FDA's survival-evidence concern. [#PR-EARNINGS-2026-08-06] https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm
Prob 85.00% • Move 5.00% • Priced-in 50.00%
EVENT2026-12-31
FDA engagement determines tovecimig's filing path
The FDA recommended a trial demonstrating survival benefit before a biliary tract cancer BLA. Compass disagrees and plans further engagement, but the existing data have not resolved the FDA's concern. Further feedback could clarify whether filing or a new trial comes first. [#8-K-2026-09-22] [#PR-2026-09-22] https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/exh_991.htm
Prob 65.00% • Move -25.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Early pipeline data test value beyond tovecimig
2026-12-31
Compass expected Q4 2026 updates from CTX-8371 cohort expansions and initial CTX-10726 clinical data. These early-stage programs offer a separate test of pipeline value but may not offset a prolonged tovecimig delay. [#PR-EARNINGS-2026-08-06] https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm
Prob 60% • Move 10% • Priced-in 20%

Risks

A longer development path could increase cash burn or financing needs; the June runway projection may change. [#PR-EARNINGS-2026-08-06] https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm
COMPANION-002 overall survival was not statistically significant despite response-rate and progression-free-survival benefits. [#PR-2026-09-22] https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/exh_991.htm
CTX-8371 and CTX-10726 remain early-stage; enrollment, readout timing and clinical outcomes are uncertain. [#PR-EARNINGS-2026-08-06] https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm
FDA may require a new survival-benefit trial before accepting a tovecimig BLA; Compass's disagreement does not establish regulatory acceptance. [#PR-2026-09-22] https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/exh_991.htm

Peers

No peer data

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…